Piflufolastat | CAS#1423758-00-2 | PET imaging agent

MedKoo Cat#: 597139 | Name: Piflufolastat

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Piflufolastat, also known as DCFPYL is a PSMA-targeted PET imaging agent for prostate cancer. Piflufolastat F-18 is a radioactive diagnostic agent used for positron emission tomography (PET) imaging. It was approved in 2021. Piflufolastat we are supplying is not radio-label compound (F-19).

Chemical Structure

Piflufolastat

CAS#1423758-00-2 (F-19)

Theoretical Analysis

MedKoo Cat#: 597139

Name: Piflufolastat

CAS#: 1423758-00-2 (F-19)

Chemical Formula: C18H23FN4O8

Exact Mass: 442.1500

Molecular Weight: 442.40

Elemental Analysis: C, 48.87; H, 5.24; F, 4.29; N, 12.66; O, 28.93

Price and Availability

Size	Price	Availability
5mg	USD 150.00	Ready to ship
10mg	USD 250.00	Ready to ship
25mg	USD 550.00	Ready to ship
50mg	USD 950.00	Ready to ship
100mg	USD 1,650.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1207181-29-0 (F18) 1423758-00-2 (F-19)

Synonym

DCFPYL; Piflufolastat;

IUPAC/Chemical Name

(((S)-1-carboxy-5-(6-fluoronicotinamido)pentyl)carbamoyl)-L-glutamic acid

InChi Key

OLWVRJUNLXQDSP-RYUDHWBXSA-N

InChi Code

InChI=1S/C18H23FN4O8/c19-13-6-4-10(9-21-13)15(26)20-8-2-1-3-11(16(27)28)22-18(31)23-12(17(29)30)5-7-14(24)25/h4,6,9,11-12H,1-3,5,7-8H2,(H,20,26)(H,24,25)(H,27,28)(H,29,30)(H2,22,23,31)/t11-,12-/m0/s1

SMILES Code

O=C(O)CC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCCCNC(C1=CC=C(F)N=C1)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Piflufolastat F-18 is indicated for people with suspected prostate cancer metastasis (when cancer cells spread from the place where they first formed to another part of the body) who are potentially curable by surgery or other therapy. Piflufolastat F-18 is also indicated for people with suspected prostate cancer recurrence based on elevated serum prostate-specific antigen (PSA) levels.

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#S22S07C30

QC Data

View QC data: current batch, Lot#S22S07C30

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Piflufolastat, also known as DCFPYL is a PSMA-targeted PET imaging agent for prostate cancer.

In vitro activity:

TBD

In vivo activity:

TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 442.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

TBD

In vitro protocol:

TBD

In vivo protocol:

TBD

1: Trinh K, Chow DZ, Park H, Habib U, Offit L, Franquet E, Almeida RR, Wang Y, Borges N, Jamal F, Jacene HA, Heidari P, Ng TSC. Evaluating the added value of concurrent contrast-enhanced diagnostic CT for PSMA-PET/CT Interpretation. Acad Radiol. 2024 Aug 14:S1076-6332(24)00571-3. doi: 10.1016/j.acra.2024.08.008. Epub ahead of print. PMID: 39147641. 2: Angappulige DH, Barashi NS, Pickersgill N, Weimholt C, Luo J, Shadmani G, Tarcha Z, Rayamajhi S, Mahajan NP, Andriole GL, Siegel BA, Kim EH, Mahajan K. Prostate-Specific Membrane Antigen-Targeted Imaging and Its Correlation with HOXB13 Expression. J Nucl Med. 2024 Aug 1;65(8):1210-1216. doi: 10.2967/jnumed.123.267301. PMID: 38936974; PMCID: PMC11294063. 3: Girod BJ, Nguyen NC. Prostatic Utricle Cysts as a Potential Pitfall in PSMA PET/CT Interpretation. Clin Nucl Med. 2024 Sep 1;49(9):e470-e472. doi: 10.1097/RLU.0000000000005340. Epub 2024 Jun 19. PMID: 38914051. 4: Bommekal S, Flynt L, Tewari SO, Surasi DSS. PSMA-Avid Desmoid Tumor of the Abdominal Wall on 18 F-Piflufolastat PET/CT. Clin Nucl Med. 2024 Jul 1;49(7):672-673. doi: 10.1097/RLU.0000000000005269. Epub 2024 May 9. PMID: 38739529. 5: Ulaner GA. Negative 18F-Piflufolastat PET/CT, But Positive 18F-Fluciclovine PET/CT, in a Patient With Biochemically Recurrent Prostate Cancer. Clin Nucl Med. 2024 May 2. doi: 10.1097/RLU.0000000000005243. Epub ahead of print. PMID: 38693630. 6: Sonar N, Sadiq Z, Kaur G, Pervaze S, Cook N. A Case of Budd-Chiari Syndrome Secondary to Tumor Thrombosis. Cureus. 2024 Mar 1;16(3):e55330. doi: 10.7759/cureus.55330. PMID: 38562314; PMCID: PMC10982124. 7: Vishakha S, Navneesh N, Kurmi BD, Gupta GD, Verma SK, Jain A, Patel P. An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021). Anticancer Agents Med Chem. 2024;24(8):590-626. doi: 10.2174/0118715206259585240105051941. PMID: 38288815. 8: Yee CW, Harvey MJ, Xin Y, Kirson NY. Cost-Effectiveness Modeling of Prostate- Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States. Pharmacoeconomics. 2024 Feb;42(2):231-247. doi: 10.1007/s40273-023-01322-2. Epub 2023 Nov 7. PMID: 37934376; PMCID: PMC10811023. 9: Lewis MC, Wale DJ, Liao E, Viglianti BL. Incidental Uptake in a Subacute Stroke on 18 F-Piflufolastat PSMA PET/CT. Clin Nucl Med. 2023 Nov 1;48(11):963-964. doi: 10.1097/RLU.0000000000004798. Epub 2023 Sep 7. PMID: 37703479. 10: Lawson TR, O'Brien SR, Pantel AR. PSMA Uptake in a Subdural Hematoma. Clin Nucl Med. 2023 Sep 1;48(9):815-817. doi: 10.1097/RLU.0000000000004777. Epub 2023 Jul 22. PMID: 37486315. 11: Oprea-Lager DE, Gontier E, García-Cañamaque L, Gauthé M, Olivier P, Mitjavila M, Tamayo P, Robin P, García Vicente AM, Bouyeure AC, Bailliez A, Rodríguez-Fernández A, Mahmoud SB, Vallejo-Casas JA, Maksud P, Merlin C, Blanc- Durand P, Drouet C, Tissot H, Vierasu I, Vander Borght T, Boos E, Chossat F, Hodolic M, Rousseau C. [18F]DCFPyL PET/CT versus [18F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study. Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3439-3451. doi: 10.1007/s00259-023-06301-5. Epub 2023 Jun 21. PMID: 37341747; PMCID: PMC10542307. 12: McLaughlin LA, Yildirim O, Rosenblum MK, Imber BS, Haseltine JM, Zelefsky MJ, Schöder H, Morris MJ, Rafelson WM, Krebs S, Moss NS. Identification of incidental brain tumors in prostate cancer patients via PSMA PET/CT. J Neurooncol. 2023 Jun;163(2):455-462. doi: 10.1007/s11060-023-04355-x. Epub 2023 May 29. PMID: 37247180; PMCID: PMC10746351. 13: Jang A, Caputo SA, Hawkins ME, Talbert JE, Sartor O. PSMA PET/CT Detection of Chondromyxoid Fibroma. Clin Nucl Med. 2023 Jun 1;48(6):545-546. doi: 10.1097/RLU.0000000000004649. Epub 2023 Apr 5. PMID: 37019118. 14: Arafa AT, Jain A, Skrobanek P, Humphrey B, Froelich JW, Antonarakis ES. Impact of piflufolastat F-18 PSMA PET imaging on clinical decision-making in prostate cancer across disease states: A retrospective review. Prostate. 2023 Jun;83(9):863-870. doi: 10.1002/pros.24527. Epub 2023 Mar 31. PMID: 36999911. 15: Nguyen A, Martinez F, Nguyen BD. Chest Wall Keloids Depicted by 18 F-Piflufolastat PET/CT Imaging. Clin Nucl Med. 2023 Jun 1;48(6):e302-e303. doi: 10.1097/RLU.0000000000004623. Epub 2023 Mar 22. PMID: 36927676. 16: Luna C, Kryvenko ON, Martinez J, Singal R, Kuker R. Uncommon Manifestation of Oligometastatic Prostate Cancer: Sister Mary Joseph Nodule. Clin Nucl Med. 2023 May 1;48(5):e225-e227. doi: 10.1097/RLU.0000000000004614. Epub 2023 Mar 6. PMID: 36881581. 17: Grossman T, Morton KA. Surveillance prostate biopsy utilizing piflufolastat F 18-PET/CT targeting in the intact prostate - A case report. Urol Case Rep. 2023 Feb 14;47:102352. doi: 10.1016/j.eucr.2023.102352. PMID: 36866336; PMCID: PMC9970888. 18: Rowe SP, Voter AF, Werner RA, Zukotynski KA, Pomper MG, Gorin MA, Solnes LB. Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT: How we do it. Can J Urol. 2023 Feb;30(1):11432-11437. PMID: 36779950. 19: Pitot MA, Broski SM, Thompson SM, Woodrum DA, Powell GM. Nodular Fasciitis: False Positive on 18F-Piflufolastat and 11C-Choline PET/CT. Clin Nucl Med. 2023 Apr 1;48(4):e209-e211. doi: 10.1097/RLU.0000000000004538. Epub 2023 Jan 12. PMID: 36728209. 20: Maliha PG, Nolet B, Ebrahim A, Abikhzer G, Chaussé G, Bahoric B, Niazi T, Probst S. Comparing digital to analog prostate-specific membrane antigen- targeted piflufolastat 18 F PET/CT in prostate cancer patients in early biochemical failure. Nucl Med Commun. 2023 Mar 1;44(3):187-193. doi: 10.1097/MNM.0000000000001652. Epub 2022 Dec 16. PMID: 36525002.